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Antibacterial effects of platelet-rich fibrin produced by
horizontal centrifugation
Mengge Feng1, Yulan Wang1, Peng Zhang1, Qin Zhao 1, Shimin Yu1, Kailun Shen1, Richard J. Miron2 and Yufeng Zhang 1,3
Platelet-rich fibrin (PRF) has been widely used owing to its ability to stimulate tissue regeneration. To date, few studies have
described the antibacterial properties of PRF. Previously, PRF prepared by horizontal centrifugation (H-PRF) was shown to contain
more immune cells than leukocyte- and platelet-rich fibrin (L-PRF). This study aimed to compare the antimicrobial effects of PRFs
against Staphylococcus aureus and Escherichia coli in vitro and to determine whether the antibacterial effects correlated with the
number of immune cells. Blood samples were obtained from eight healthy donors to prepare L-PRF and H-PRF. The sizes and
weights of L-PRF and H-PRF were first evaluated, and their antibacterial effects against S. aureus and E. coli were then tested in vitro
using the inhibition ring and plate-counting test methods. Flow-cytometric analysis of the cell components of L-PRF and H-PRF was
also performed. No significant differences in size or weight were observed between the L-PRF and H-PRF groups. The H-PRF group
contained more leukocytes than the L-PRF group. While both PRFs had notable antimicrobial activity against S. aureus and E. coli,
H-PRF demonstrated a significantly better antibacterial effect than L-PRF. Furthermore, the antimicrobial ability of the PRF solid was
less efficient than that of wet PRF. In conclusion, H-PRF exhibited better antibacterial activity than L-PRF, which might have been
attributed to having more immune cells.
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INTRODUCTION
Dental implants are increasingly accepted by patients with
missing teeth, with high survival and success rates1. However,
the loss of bone and soft tissue often limits dental implant
placement. In such cases, clinicians perform soft tissue transplan-
tation, guided bone regeneration (GBR), or sinus augmentation to
address these limitations. Although most of these techniques
provide predictable results, improvements in wound healing and
bone and soft tissue regeneration are needed both after tooth
extraction and during implant placement. Recently, second-
generation platelet-rich fibrin (PRF) was proposed as a new
implant therapeutic strategy for promoting implant healing and
bone and soft tissue integration2,3. PRF or leukocyte- and platelet-
rich fibrin (L-PRF) is obtained from the inpatients’ blood and
typically centrifuged at a relative centrifugal field (RCF)-max/g-
force of 700 for 12 min without any additives4,5. PRF not only acts
as a three-dimensional fibrin scaffold but also contains numerous
autologous cells, such as platelets, macrophages, and neutrophils6.
Furthermore, the fibrin matrix of PRF serves as a “storage” scaffold
for the gradual release of growth factors over time7. Given its
conformance to the criteria for tissue engineering, PRF has been
widely used in dentistry, showing great therapeutic potential for
both soft and hard tissue regeneration4,8,9.
However, considering that the oral cavity harbors hundreds of
microbes10,11, wounds healing after tissue regeneration are always
at risk of infection. Based on previous reports, Staphylococcus
aureus and Escherichia coli are related to these infections12–14. For
patients subjected to implant surgery, this infection often leads to
the inflammation of soft tissue around the implant and
progressive bone loss, resulting in implant loss15. In anti-
infection immunity, immune cells play an important role by
acting as a bodily defense mechanism. PRF contains numerous
immune cells, which may inhibit the infection associated with
implant placement. Although several studies have reported that
PRF has an antibacterial effect, there are no reports comparing the
antibacterial effects of PRFs prepared using different centrifuga-
tion methods or protocols. Furthermore, whether the antibacterial
effect of PRF is correlated with the number of immune cells
present in the final composition remains unexplored16,17.
Recently, horizontal centrifugation of PRF was shown to result in
better cell layer separation and to minimize cell accumulation on
the distal surfaces of centrifugation tubes, which prevents proper
cell layer separation5,18–20. In horizontal centrifugation, the swing-
out bucket produces a completely horizontal tube. This can result
in substantial differences between the minimum and maximum
centrifugal radii of the tube, which causes differences between the
RCF-min and RCF-max, respectively. Furthermore, we previously
demonstrated that horizontal centrifugation led to a fourfold
increase in immune cell numbers when compared to those
achieved with fixed-angle centrifugation5. Considering that
platelets and leukocytes are crucial in immune defense against
infection, PRF obtained by horizontal centrifugation (H-PRF) may
exert greater antibacterial effects than PRF or L-PRF.
This study aimed to accomplish the following: to compare the
antimicrobial effects of PRF prepared by horizontal centrifugation
(H-PRF) and L-PRF produced on a fixed-angle centrifuge against
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Staphylococcus aureus and Escherichia coli in vitro and to
determine whether the antibacterial effects were correlated with
the immune cell numbers in H-PRF and L-PRF.
RESULTS
Preparation of L-PRF and H-PRF
After centrifugation, the blood samples were separated into
various layers. Using fixed-angle centrifugation, an angular red
blood layer was observed following L-PRF preparation, whereas a
horizontal division between the PRF and red blood cell layers was
found in the H-PRF group prepared by horizontal centrifugation
(Fig. 1a). No significant differences in size or weight were observed
between the L-PRF and H-PRF groups when both groups were
centrifuged in 10 mL glass tubes (P > 0.05, Fig. 1b).
Antibacterial properties of L-PRF and H-PRF
The colony-forming unit (CFU) measurements indicated that both
PRF clots had antibacterial effects against S. aureus and E. coli
(Fig. 2a, b). Compared with L-PRF, H-PRF showed a significant and
pronounced increase in activity against both S. aureus and E. coli.
Next, the antibacterial activities of the PRF clots were analyzed
by direct incubation on bacterial culture plates. After 24 h of
incubation, the antimicrobial activity was demonstrated by
investigating the clear zones from the inhibition rings around
the L-PRF and H-PRF groups (Fig. 3a). The width of the inhibition
zone in the H-PRF group was significantly larger than that in
the L-PRF group for both bacteria. Furthermore, the inhibition
zone against E. coli was wider than that against S. aureus (P < 0.05,
Fig. 3b).
Antibacterial properties of different layers from L-PRF and H-PRF
Previously, we observed that the cell contents in each PRF layer
were different, with H-PRF harboring up to four times more
leukocytes than L-PRF5. Therefore, we divided the liquid-state PRF
into five equal portions after centrifugation in plastic tubes to
verify whether the antibacterial properties were different in each
layer (Fig. 4a). The plate-counting assay showed that each PRF
layer exhibited some antibacterial activity against S. aureus and
E. coli. However, the antimicrobial effects of the five layers of each
PRF varied significantly. Our CFU results showed that the bacterial
count of layer five in L-PRF was the lowest among all those
analyzed. However, there were no significant differences in the
antibacterial effects of the different H-PRF layers on the growth of
S. aureus and E. coli (Fig. 4b–e).
Flow-cytometric analysis
Figure 5a and Table 1 show the gates and numbers of various
immune cells from various layers. In general, the number of total
immune cells in H-PRF was tenfold higher than that in L-PRF
(102,076 vs. 9778), particularly in the upper layers (Fig. 5b). For
L-PRF, the majority of immune cells were located only within the
fifth layer nearest to the buffy coat, whereas in the H-PRF group,
the number of immune cells was increased in all layers but also
more evenly distributed throughout the upper layers (Fig. 5b and
Table 1). The proportions of immune cell subtypes were different
in each layer in the L-PRF and H-PRF groups (Fig. 5c).
Antibacterial effects of PRF solid and exudate components from
each layer in L-PRF and H-PRF
PRF clots were then separated into either solid or exudate
components and further subjected to antimicrobial assays
(Fig. 6a). The solid and exudate components from L-PRF and H-
PRF had different antibacterial properties (Fig. 6b–d). Consistent
with previous results, the antibacterial effects of the solid and
exudate components against E. coli were better than those against
S. aureus. Furthermore, the relative inhibition rates of H-PRF
exudates were significantly better than those of L-PRF, particularly
for E. coli (Fig. 6c, d).
DISCUSSION
Recently, PRF has been considered as a potential strategy for
promoting tissue regeneration around implants2. However,
implants surrounding tissues are exposed to various bacterial
infiltrations; hence, strategies to combat bacterial overload are
needed. In the existing literature, only a few reports have
discussed the antibacterial effects of PRF, especially when
compared to the number of studies investigating its regenerative
potential. PRF is a complex mixture of cells (platelets and various
white blood cells), a three-dimensional fibrin scaffold and a variety
of active growth factors and plasma proteins21. However, the























Fig. 1 Photos of leukocyte- and platelet-rich fibrin (L-PRF) and H-
PRF. a Photos of platelet-rich fibrin (PRF) obtained after centrifuga-
tion by both protocols. Note the horizontal-layer centrifugation in H-
PRF versus the angular centrifugation in L-PRF. b Weight and size


























Fig. 2 Antibacterial properties of leukocyte- and platelet-rich fibrin (L-PRF) and H-PRF. a, b Photos and quantitative analysis of S. aureus and
E. coli bacterial colonies incubated with L-PRF or H-PRF clots for 4 h. *P < 0.05, **P < 0.01, and ***P < 0.001
Antibacterial: L-PRF vs H-PRF
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2































Fig. 3 Antibacterial effects of leukocyte- and platelet-rich fibrin (L-PRF) and H-PRF. a, b Photos and quantification of the inhibition zones
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Fig. 4 Antibacterial properties of different layers of platelet-rich fibrin (PRF) prepared in accordance with leukocyte- and platelet-rich fibrin
(L-PRF) and H-PRF protocols. a Illustration of the stratified sampling procedure. PRF was equally divided into five layers. b, c Photos and
quantitative analysis of the S. aureus bacterial colony incubated with each L-PRF or H-PRF layer for 4 h. d, e Photos and quantitative analysis of
the E. coli bacterial colony incubated with each L-PRF or H-PRF layer for 4 h. *P < 0.05, **P < 0.01, and ***P < 0.001
Antibacterial: L-PRF vs H-PRF
Feng et al.
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antibacterial properties of PRF are relatively unknown. Therefore,
this study aimed to compare the antimicrobial activities of PRFs
prepared via fixed-angle (L-PRF) and horizontal (H-PRF) centrifu-
gation against Gram-positive and Gram-negative bacteria and to
determine whether the antibacterial effects were correlated with
the number of immune cells.
It is well-known that PRFs contain accumulated platelets.
Platelets not only generate oxygen metabolites and antimicrobial
peptides directly targeting bacterial cells but also play a role in the
binding, aggregation, and internalization of pathogens to improve
clearance via the bloodstream22–24. Burnouf et al.16 reported that
platelet concentrates inhibited the growth of S. aureus, E. coli,
Pseudomonas aeruginosa, and Klebsiella pneumonia. In addition,
platelet gel supernatants have been shown to exert bactericidal
effects against S. aureus25. In contrast, leukocytes are well-known
white blood cells that have a considerable bactericidal ability.
Upon bodily infection, activated neutrophils migrate to the
infection site and release active antibacterial substances to
promote the phagocytosis of foreign pathogens. Leukocytes
produce a variety of antimicrobial peptides and enzymes,
including lactoferrin, defensins, BPI azurocidin/heparin-binding
protein, cathelicidins, phospholipase A2, and calprotectin26.
Moreover, plasma contains a complement system, which can
activate the complement cascade to facilitate bacterial cell lysis
and leukocyte recruitment for humoural defense against infec-
tious agents27.
We used the classic inhibition ring test and plate-counting
test to verify the antibacterial effect according to a previous
report28–30. Our results indicated that L-PRF and H-PRF exerted











































































































































































































































































































































































































































































































































































































































Fig. 5 Flow-cytometric analysis of immune cells in each layer of leukocyte- and platelet-rich fibrin (L-PRF) and H-PRF. a Flow-cytometric
profiles of different layers stained for immune cells (CD45+ ), T cells (CD3+ ), NK cells (CD16+ ), B cells (CD19+ ), neutrophils (CD11b+ ;
CD14+ ), and monocytes (CD11b+ ; CD14−). b Quantitative analysis of the total number of immune cells in each L-PRF and H-PRF layer. c The
percentages of T cells, NK cells, B cells, neutrophils, and monocytes among total immune cells in each L-PRF and H-PRF layer
Antibacterial: L-PRF vs H-PRF
Feng et al.
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compared with L-PRF, H-PRF showed a significantly better ability
to protect against E. coli regardless of whether it was in the
supernatant or gel (fibrin) state. Although the majority of blood
platelets and leukocytes remain within the PRF membranes, the
exudate also contains small amounts of cellular components (2.5%
of platelets and 0.9% of leukocytes)31.
Previous research has shown that the platelets and leukocytes in
PRFs obtained by horizontal centrifugation accumulate cells up to
four times more effective than those obtained by fixed-angle
centrifugation. In our study, flow-cytometric analysis provided more
accurate data regarding immune cell types, which were obtained
by centrifugation, and further confirmed that the total immune cell
numbers were increased almost tenfold in H-PRF compared with L-
PRF. Researchers have reported that the antibacterial properties of
PRF can be divided into two parts: (1) the release of antimicrobial
peptides entrapped initially in the fibrin matrix along with PRF
degradation and (2) the antimicrobial factors produced constantly
from the cells inside the fibrin matrix28. The increased leukocyte
counts within H-PRF were hypothesized to dramatically enhance
the antimicrobial properties of PRF compared with those achieved
with traditional L-PRF protocols. This finding was also supported by
Cieślik-Bielecka et al.32.
Previously, using complete blood count analysis, the cell
content in each upper layer of PRF was shown to differ5. We
divided the PRFs into five equal portions to investigate the
differences in immune cell numbers and their antibacterial effects
and to explore whether the antibacterial properties correlated
with these cell numbers. The upper layer of L-PRF had the fewest
immune cell numbers, which correlated well with the antibacterial
properties of that layer and further demonstrated weaker activity
when compared with that of the other layers. Although the
numbers of immune cells in L-1 and L-5 from H-PRF were nearly
the same, the antibacterial effect of L-5 was increased, particularly
in the exudate. Flow-cytometric analysis showed that the cell
proportions were significantly different between L-1 and L-5,
probably because various white blood cells had different cell
densities. The fifth layer of H-PRF contained more T cells than the
first layer. T cells are directly implicated in the elimination of
microbial pathogens by releasing cytotoxic granules and bacter-
iostatic or lytic molecules33,34. Moreover, T cells can regulate other
immune cells, including dendritic cells, macrophages, B cells and
other subtypes of T cells35–37. We attributed the improved
antibacterial ability of L-5 to the good regulatory effects of
T cells on other immune cells found in the layer closest to the
buffy coat in H-PRF. Furthermore, both the solid-membrane
component and the exudate from H-PRF were antibacterial, which
indicated that not only the cell components of H-PRF but also the
secretions of cytokines and/or complement proteins had strong
antimicrobial properties. Although we found that the antibacterial
effect of PRF is related to the number of immune cells, the exact
mechanisms have not been elucidated, and further experiments
must be conducted in the future.
CONCLUSION
Our study demonstrated that the PRF prepared by horizontal
centrifugation exhibited significantly better antibacterial activities
against both S. aureus and E. coli than traditional L-PRF. The
increased antibacterial effects of H-PRF were not only attributed to
the increase in leukocytes but also correlated with released
exudate components. The antimicrobial ability of the PRF solid
was less efficient than that of wet PRF, which indicated that the
liquid components of PRF could be retained to enhance
antibacterial properties during routine clinical use.
MATERIALS AND METHODS
Preparation of PRF
Blood samples were collected from eight volunteers, including
three males and five females (average age of 25) after informed
consent was provided. All the protocols used in this study were
approved by the Ethics Committee of the School and Hospital of
Stomatology, Wuhan University (B52/2020). All participants were
in good health, were nonsmokers, had no symptoms of infection,
and had taken no antibiotics for at least 3 months prior to the
experiments.
In this study, the two types of PRF were prepared with two
different centrifugation devices. In the present study, the plastic
tubes were used to obtain the liquid form of PRF, while glass tubes
were used to obtain the solid form of PRF according to previous
reports4,5,38. L-PRF was obtained by a fixed-angled centrifuge
(Chixin Biotech, Wuhan, China) at a g-force of 700 for 12min at
room temperature according to previous reports4,5,38. H-PRF was
collected by a horizontal centrifuge at a g-force of 700 for 8 min at
room temperature according to a previous report5.
PRF size and weight
L-PRF and H-PRF clots were obtained by centrifugation in 10-mL
glass tubes (Chixin Biotech, Wuhan, China). After centrifugation,
the red blood clots attached to the yellow PRF clots were gently
removed6,39. Each PRF clot was measured with a Vernier caliper
and weighed40. All paired L-PRF and H-PRF samples used in the
experiment were obtained from the same donors.
Bacterial preparation
S. aureus (ATCC BAA-1758) and E. coli (MG 1655) were grown in LB
broth at 37 °C under aerophilic conditions. The optical density at
600 nm was measured by a microplate reader (PowerWave XS2;
BioTek, Winooski, VT). The bacterial suspension was diluted to 1 ×
106 or 1 × 105 CFU·mL−1 for experimental use.
Table 1. Cell counts of L-PRF and H-PRF by flow-cytometric analysis
Group Layer Immune cells T cell NK cell B cell Neutrophil Monocyte
L-PRF L-1 445 14 10 1 2 18
L-2 557 10 20 1 4 16
L-3 2 200 6 7 1 2 70
L-4 650 5 5 1 6 37
L-5 5 926 133 79 7 57 318
H-PRF L-1 24 777 2 114 39 181 83 1 095
L-2 21 191 1 995 19 176 67 1 051
L-3 14 109 1 896 33 165 78 308
L-4 17 940 1 917 25 196 68 785
L-5 24 059 2 870 51 249 128 1 026
Antibacterial: L-PRF vs H-PRF
Feng et al.
5
International Journal of Oral Science           (2020) 12:32 
Inhibition ring test of the whole PRF clot
L-PRF and H-PRF clots were obtained by centrifugation in 10-mL
glass tubes. L-PRF and H-PRF clots were compressed and
converted into a standardized membrane with a thickness of
1 mm to determine their antibacterial abilities28. A total of 500 μL
of S. aureus or E. coli (1 × 106 CFU· mL−1) was cultured on LB agar
plates. The L-PRF or H-PRF membranes on the surface of the LB
agar plate were in direct contact with S. aureus or E. coli. The
samples were incubated for 24 h. The length and width of each
PRF membrane were measured at baseline after 24 h using
ImageJ. Horizontal (length) and vertical (width) lines were drawn
at a 90° angle from the midpoint of the membrane28.
Inhibition ring test of the PRF exudate and solid PRF
The L-PRF and H-PRF clots were obtained by centrifuging the
blood in 10-mL glass tubes. The obtained L-PRF and H-PRF clots
were first divided into five equal parts to compare the
antibacterial properties of the different PRF layers. Then, each
PRF clot layer was drained into the exudate and solid parts
(containing nearly no exudate). Ten microlitres of exudate from
each clot were pipetted onto the filter paper29. Each drained L-PRF
and H-PRF clot layer was then compressed and converted into a
1-mm-thick membrane. A total of 500 μL of S. aureus or E. coli
(1 × 106 CFU· mL−1) was cultured on LB agar plates. After 30 min,
the PRF membrane or filter paper was placed directly on the
surface of the LB agar plate. The incubation time was also 24 h.
The length and width of each PRF membrane or filter paper
were measured by ImageJ. The calculation procedure was the
same as that described above.
Plate-counting test of the whole PRF clot
L-PRF and H-PRF clots were obtained by centrifugation in 10-mL
glass tubes. L-PRF and H-PRF clots were mixed with 4 mL of
bacteria (1 × 105 CFU· mL−1) using a shaking incubator for 4 h
(37 °C, 150 r·min−1) to investigate their antibacterial properties.
Afterward, 100 µL of the sample was diluted with 900 µL of
phosphate-buffered saline (PBS), and 30 μL of the sample was






















































































































Fig. 6 The antibacterial properties of solid and liquid layers obtained via leukocyte- and platelet-rich fibrin (L-PRF) and H-PRF protocols.
a Illustration of the stratified sampling and incubation procedure. The total platelet-rich fibrin (PRF) clot was divided into five equal portions
and then separated into solid and exudate components. b–d Photos and quantitative analysis of the inhibition zones of each L-PRF and H-PRF
layer against S. aureus and E. coli after incubation for 24 h. *P < 0.05, **P < 0.01, and ***P < 0.001
Antibacterial: L-PRF vs H-PRF
Feng et al.
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Plate-counting test of the liquid form of PRF
The liquid forms of L-PRF and H-PRF were obtained by centrifugation
in plastic tubes (Chixin Biotech, Wuhan, China) to detect the
antibacterial properties of each layer. Then, the different layers were
partitioned by sequentially pipetting 870 μL (±10 μL) from the top
layer down to the red blood cell interface (not pipetting the red blood
cell layer). One hundred microlitres of L-PRF (1-5), H-PRF (1-5), or PBS
were mixed with 100 µL of S. aureus or E. coli (1 × 106 CFU·mL−1) in
1.5-mL sterile EP tubes. A final 1mL sample in PBS was obtained at a
final bacterial concentration of 1 × 105 CFU·mL−1. After incubating
the tubes at 37 °C at 150 r·min−1 for 4 h, 100 µL of the sample was
collected and diluted with 900 µL of PBS. Then, 30 µL of each sample
was added to an LB agar plate and cultured at 37 °C overnight for
CFU counting41,42.
Preparation of single-cell suspensions and flow-cytometric analysis
The L-PRF and H-PRF layers were obtained by centrifugation in
10-mL plastic tubes and divided into five equal portions. Cells
from each layer were then centrifuged. Afterward, the cells were
resuspended and incubated for 30 min on ice with FITC anti-
human CD45 (1:200, Biolegend, no. 304006), PE anti-human CD3
(1:200, Biolegend, no. 300308), Pacific Blue™ anti-mouse/human
CD11b (1:200, Biolegend, no. 101224), Alexa Fluor® 700 anti-
human CD14 (1:200, Biolegend, no. 325614), PE/Cy7 anti-human
CD16 (1:200, Biolegend, no. 302015) and APC anti-human CD19
(1:200, Biolegend, no.302212) antibodies to quantify the various
blood cell types. Finally, flow-cytometric analysis was performed
using a BD LSRFortessa instrument (USA), and the results were
analyzed by FlowJo 10.
Statistical analysis
The data were analyzed with GraphPad Prism software 7.0
(La Jolla, CA). The t test was used to determine statistical
significance. Data are reported as the mean ± SD. *P < 0.05,
**P < 0.01, and ***P < 0.001 considered statistically significant.
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